This content is from the original 2022 HFSA AHFTC Board Certification Review Course

2023 BCR Spotlight: Shock/MCS
Utilizing presentations from the 2022 HFSA AHFTC Board Review course, 2023 BCR Spotlight: Shock/MCS will provide overview of the selection, management, and complications of acute and durable mechanical circulatory support. The seminar will begin with a discussion on defining the phenotype of advanced heart failure and patient selection for advanced therapies. Participants will learn about immunology basics, including PRA, sensitization, and crossmatch, and the cellular and antibody-mediated rejection associated with heart transplantation. It will also cover the management of immunosuppression and drugs, including dosing strategies and monitoring, and post-transplant management, including long-term follow-up and potential complications.

This program is intended for physicians, nurses, nurse practitioners, physician assistants, and advanced practice professionals that provide care to patients with heart failure.

Program Co-Chairs
•    Akshay S. Desai, MD, MPH, FHFSA - Brigham and Women’s Hospital, Boston, MA
•    Maria Rosa Costanzo, MD - Advocate Heart Institute, Naperville, IL                  
•    Nancy Sweitzer, MD, PhD, FHFSA - Washington University School of Medicine, St. Louis, MO
•    Jonathan Rich, MD, FHFSA - Northwestern University Feinberg School of Medicine, Chicago, IL

Speakers
•    Daniel Burkhoff, MD, PhD - Cardiovascular Research Foundation, New York, NY
•    Jennifer Cowger, MD, MS - Wayne State University, Detroit, MI
•    Joseph Rogers, MD - Texas Heart Institute, Houston, TX
•    Nancy Sweitzer, MD, PhD, FHFSA - Washington University School of Medicine, St. Louis, MO

Course Details
• Cardiogenic Shock Management – N. Sweitzer
• MCS I: Durable MCS Devices and Outcomes – J. Rogers
• MCS II: Temporary Support Devices and ECMO for the Boards – J. Cowger
• MCS III: MCS Complications and Patient Management – J. Cowger
• MCS IV: Interactive Shock and Device Management – D. Burkhoff, J. Cowger, J. Rogers, N. Sweitzer

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 3.00 AMA PRA Category 1 Credits™.  
 
The Heart Failure Society of America designates this live activity for a maximum of 3.00 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 3.00 MOC points in the Maintenance of Certification (MOC) program.

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:
•    Jonathan Rich, MD, FHFSA
•    Joseph Rogers, MD
•    Nancy Sweitzer, MD, PhD, FHFSA

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:

• Daniel Burkhoff, MD, PhD – Consultant: CardioDyme, ZOLL Medical; Research Support: Abiomed
• Maria Rosa Costanzo, MD, FHFSA – Consultant: Nuwellis; Board Member: Nuwellis; Advisory Panel: Boehringer Ingeheim; Research Support: Abbott Laboratories, Novartis, V-Wave
• Jennifer Cowger, MD, MS – Research Grant: Abbott Laboratories, Medtronic, Endotronix, Procyrion, Bivacor; Speaker/Honoraria: Abbott, Zoll, Bioventrix; Ownership/Interest: Procyrion; Consultant/Advisory Board: Abbott, Medtronic, Zoll, Endotronix, Procyrion, Bioventrix, Corware, Nuwellis, Bivacor
• Akshay S. Desai, MD, MPH, FHFSA – Consultant: Abbott Laboratories, AstraZeneca, BayerAG, Novartis, Cytokinetics, DalCor Pharmaceuticals, GloaxoSmithKline, Merck, Relyspa, Regenron Pharmaceuticals, Verily, Biofourmis, Sun Pharmaceuticals, Lupin Pharmaceuticals, Avidity; Research Support: Abbott Laboratories, AstraZeneca, Bayer AG, Novartis, Alnylam Pharmaceuticals

Off-Label Disclosure

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.